Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rep. Paulsen Re-Introduces Bill To Repeal Device Tax

Executive Summary

The Minnesota congressman is taking another stab at chopping off the 2.3 medical device excise tax as part of the wider Obamacare repeal actions anticipated for the new Congress.

You may also be interested in...



Lobbyists Again Coordinate Device Tax Attack

AdvaMed and MDMA, two rivaling lobby groups, have again come together against a common enemy: the Obamacare medical device excise tax. The groups simultaneously released survey results that argue that permanently repealing the tax would be a boon for their member companies and innovation.

Congress To Focus On Cures And MACRA Oversight, MDUFA In 2017

Congressional health committees will spend time in 2017 focusing on oversight of agencies' implementation of the 21st Century Cures Act and the Medicare Authorization and CHIP Reauthorization Act, as well as five-year reauthorization of the medical device and prescription drug user fee acts.

Two-Year Ban On Device Tax Approved In Tax-Extenders Bill

Congress passed a two-year moratorium on the 2.3% device excise tax as part of a tax-extenders package, Dec. 18, and President Obama was expected to sign it. The legislation also includes a permanent extension of the research & development tax credit.

Topics

UsernamePublicRestriction

Register

MT104266

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel